These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35430765)

  • 1. Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary.
    Bochtler T; Wohlfromm T; Hielscher T; Stichel D; Pouyiourou M; Kraft B; Neumann O; Endris V; von Deimling A; Stenzinger A; Krämer A
    Genes Chromosomes Cancer; 2022 Sep; 61(9):551-560. PubMed ID: 35430765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma.
    Detlefsen S; Boldt HB; Burton M; Thomsen MM; Rasmussen LG; Ørbeck SV; Pfeiffer P; Mortensen MB; de Stricker K
    Hum Pathol; 2023 Dec; 142():68-80. PubMed ID: 37977512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
    Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
    Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
    ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup.
    Lee JC; Lu TP; Changou CA; Liang CW; Huang HN; Lauria A; Huang HY; Lin CY; Chiang YC; Davidson B; Lin MC; Kuo KT
    Mod Pathol; 2016 Sep; 29(9):1070-82. PubMed ID: 27255164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
    Westphalen CB; Federer-Gsponer J; Pauli C; Karapetyan AR; Chalabi N; Durán-Pacheco G; Beringer A; Bochtler T; Cook N; Höglander E; Jin DX; Losa F; Mileshkin L; Moch H; Ross JS; Sokol ES; Tothill RW; Krämer A
    ESMO Open; 2023 Dec; 8(6):102035. PubMed ID: 37922692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma.
    Chen X; Ou Z; Wang L; Zhang Z; Fan X; Liu H; Wang W; Zhang Y; Zhu J; Liang X; Lou F; Cao S; Yao Y; Wang H; Yao X
    Mol Carcinog; 2022 Mar; 61(3):311-321. PubMed ID: 34729830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated Analysis of Copy Number Variation, Microsatellite Instability, and Tumor Mutation Burden Identifies an 11-Gene Signature Predicting Survival in Breast Cancer.
    Jin X; Yan J; Chen C; Chen Y; Huang WK
    Front Cell Dev Biol; 2021; 9():721505. PubMed ID: 34650974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy.
    Zhang Q; Zhang J; Liu Z; Wang J; Wang F; Wang T; Shi F; Su J; Zhao Y
    Drug Des Devel Ther; 2023; 17():3507-3522. PubMed ID: 38046281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
    Stahler A; Stintzing S; von Einem JC; Westphalen CB; Heinrich K; Krämer N; Michl M; Modest DP; von Weikersthal LF; Decker T; Kiani A; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Kaiser F; Kirchner T; Jung A; Heinemann V
    Eur J Cancer; 2020 Sep; 137():250-259. PubMed ID: 32810748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
    Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a Hybrid Capture-Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes.
    Kroeze LI; de Voer RM; Kamping EJ; von Rhein D; Jansen EAM; Hermsen MJW; Barberis MCP; Botling J; Garrido-Martin EM; Haller F; Lacroix L; Maes B; Merkelbach-Bruse S; Pestinger V; Pfarr N; Stenzinger A; van den Heuvel MM; Grünberg K; Ligtenberg MJL
    J Mol Diagn; 2020 Jun; 22(6):757-769. PubMed ID: 32205293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromothripsis and focal copy number alterations determine poor outcome in malignant melanoma.
    Hirsch D; Kemmerling R; Davis S; Camps J; Meltzer PS; Ried T; Gaiser T
    Cancer Res; 2013 Mar; 73(5):1454-60. PubMed ID: 23271725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.